The Pharma Data

JANUARY 10, 2021

LUXEMBOURG–( BUSINESS WIRE )– Eurofins GeneScan Technologies (Paris:ERF) announces that the VIR Seek SARS-CoV-2 Solution has been evaluated and approved by the AOAC Performance Tested Methods SM (PTM) Program on December 29, 2020 and awarded Emergency Response Validation PTM certification number 122006.

RNA 52

RNA Virus Research 52

The Pharma Data

OCTOBER 23, 2020

23, 2020 — In a Society for Healthcare Epidemiology of America white paper, published online Oct. The authors recommended viral load thresholds of 1,000 IU for hepatitis B virus (HBV), hepatitis C virus (HCV) RNA undetectable for HCV, and suppressed viral RNA for HIV for determining any restrictions on HCP practice.

RNA 52

RNA Virus Vaccine Treatment 52

The Pharma Data

OCTOBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. , The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., BOSTON, Oct. Chief Executive Officer and Founder of Atea Pharmaceuticals.

RNA 52

RNA Pharmaceuticals Virus Small Molecule 52

Drug Target Review

MARCH 21, 2024

Because mRNA is not a virus, it doesn’t have to meet biosafety requirements for manufacturing and administration that an AAV approach would need. Additionally, the COVID-19 RNA vaccines have already demonstrated how safe RNA can be, and we look forward to seeing additional safety data on RNA approaches as the field continues to grow.

Therapies 64

Therapies RNA Immune Response Treatment 64

The Pharma Data

AUGUST 16, 2021

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

JANUARY 11, 2021

Moderna is following up on the success of its messenger RNA-based COVID-19 vaccine with plans to develop inoculations for numerous other infectious diseases, the company said Monday. 18, 2020 ). It has also received temporary or conditional authorization in the UK and in the EU ( DID , Jan.

Vaccine 52

Vaccine Clinical Trials Virus RNA 52

The Pharma Data

OCTOBER 19, 2020

20, 2020 12:00 UTC. Spectrum’s self-contained saliva collection kit provides critical sample consistency while suspending and neutralizing viral RNA transcripts completely inactivating the live virus. Qualified commercial RNA extraction chemistries include Perkin Elmer, Thermo Fisher, Roche, and Qiagen.

RNA 52

RNA DNA Engineering Virus 52

Broad Institute

NOVEMBER 6, 2024

More than 230,000 patients in the US were treated with ICIs in 2020, and that number has likely grown since then as the FDA has approved more than 80 indications for these medicines. Tags: Cancer RNA sequencing Paper Cited Blum S, Zlotoff D, et al. Immune responses in checkpoint myocarditis across heart, blood and tumour.

Immune Response 118

Immune Response Medical Schools Clinical Trials Treatment 118

The Pharma Data

JUNE 25, 2021

The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. “In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” More than half of the cases (57%) were caused by Variants of Concern.

Vaccine 52

Vaccine Trials Immune Response Virus 52

Codon

AUGUST 27, 2024

When doctors sequenced the DNA and RNA found in Alice’s blood and synovial fluid—the liquid that surrounds and lubricates joints—they found abnormally low levels of genes encoding iron-storing proteins and high levels of epidermal growth factor receptor RNA.

DNA 81

DNA Laboratories Hospitals Virus 81

Broad Institute

JANUARY 30, 2024

He has also emerged in recent years as a skilled and relatable science communicator, renowned for his efforts at Broad and beyond during the COVID-19 pandemic to unpack the fast-moving research on the new virus in an accessible way and give practical advice about masking, vaccines, and other public health measures.

Hospitals 137

Hospitals Medical Schools Virus Science 137

The Pharma Data

DECEMBER 3, 2020

4, 2020 08:00 UTC. A global Phase 2/3 efficacy study of the S-Trimer vaccine candidate in combination with GSK’s pandemic adjuvant system is expected to begin in December 2020. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. CHENGDU, China.–(

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

OCTOBER 30, 2020

30, 2020 — Viral load was decreased at day 11 for patients with mild or moderate COVID-19 who received a single intravenous infusion of virus-neutralizing monoclonal antibody versus placebo, according to a study published online Oct. percent of viral RNA at day 11. © 2020 HealthDay. Posted: October 2020.

RNA 52

RNA Virus Hospitals Trials 52

The Pharma Data

NOVEMBER 17, 2020

17, 2020 — As the U.S. After getting the virus under control, California Gov. Until now, Reynolds had ignored infectious disease experts who say masks are one of the most effective tools to control the spread of the virus, the Post reported. © 2020 HealthDay. Posted: November 2020. TUESDAY, Nov.

Vaccine 52

Vaccine Virus RNA Hospitals 52

The Pharma Data

MAY 17, 2021

14, 2020 ). 2 virus and the variant first identified in South Africa. Sanofi has also entered into vaccine manufacturing partnerships to help produce the Pfizer/BioNTech, Moderna and Johnson & Johnson shots ( DID , April 13 ), and it is developing a messenger RNA-based vaccine candidate with Translate Bio.

Vaccine 40

Vaccine Immune Response RNA Virus 40

The Pharma Data

JUNE 26, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

MARCH 20, 2021

Biogazelle, an innovative bioanalytical services company offering RNA and. In April 2020, Biogazelle introduced a high-throughput, modular and scalable SARS-CoV-2 RT-qPCR. Ghent University Hospital for SARS-CoV-2 virus screening. Bioinformatics in the Faculty. of Medicine and Health Sciences (Ghent University) and. therapeutics.

Laboratories 52

Laboratories Virus RNA Bioinformatics 52

The Pharma Data

NOVEMBER 18, 2020

18, 2020 – The first rapid coronavirus test that can be taken at home with results delivered in 30 minutes was cleared for emergency use by the U.S. Lab tests that look for the coronavirus’s genetic material using a technique called polymerase chain reaction (PCR) are still considered the gold standard for detecting the virus.

FDA Approval 52

FDA Approval FDA Vaccine Virus 52

The Pharma Data

DECEMBER 5, 2020

5, 2020 — A pair of new gene therapies promise a potentially lasting cure for sickle cell disease by subtly altering the genetic information in patients’ bone marrow cells, researchers report. Bluebird’s method “uses a virus to drop an entire gene encoding a new hemoglobin. © 2020 HealthDay.

Therapies 52

Therapies Disease Medical Schools Virus 52

The Pharma Data

AUGUST 31, 2020

Basel, 1 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Among them, more than 160,000 people did not know their HIV status, and only 53 percent were virally suppressed having low amounts of virus circulating in their blood. Reviewed June 8, 2020. Accessed July, 24 2020. J Clin Virol.

FDA Approval 52

FDA Approval FDA Virus Disease 52

The Pharma Data

SEPTEMBER 9, 2020

Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge. The information contained in this release is as of September 9, 2020.

Vaccine 52

Vaccine RNA Clinical Trials Trials 52

The Pharma Data

MARCH 20, 2021

Coronaviruses are RNA viruses and include common human coronaviruses, severe acute respiratory syndrome-CoV (SARS-CoV), Middle East respiratory syndrome-CoV (MERS-CoV) and SARS-CoV-2 ( 1 ). Detection of virus-specific antibodies allows for diagnosis of recent symptomatic or even asymptomatic infections. INTRODUCTION.

Virus 52

Virus Assay Development Laboratories RNA 52

Drug Target Review

SEPTEMBER 25, 2024

Analysis of transcriptional changes using RNA sequencing further confirmed that TT125-802 suppresses key non-oncogene resistance mechanisms including transcriptional networks around stemness, epithelial-mesenchymal transition (EMT), and transforming growth factor beta (TGFβ) signalling. British Journal of Cancer [Internet].

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

The Pharma Data

MAY 17, 2021

The drug companies had hoped to have regulatory approval for their jab in the first half of this year, but interim results from a Phase 1/2 study, released in December 2020, had shown an “insufficient” ? response in the over-50s, the age group deemed at higher risk for contracting the severe form of the virus. .

Immune Response 52

Immune Response Vaccine Trials RNA 52

The Pharma Data

JULY 29, 2021

for the same period in 2020. This was primarily driven by the impact of higher in-process research and development (“IPR&D”) expenses in the second quarter 2020 related to the Forty Seven, Inc. billion as of December 31, 2020. billion compared to the same period in 2020. Second Quarter 2021 Financial Results.

Science 52

Science Production Treatment FDA 52

The Pharma Data

SEPTEMBER 1, 2020

Basel, 1 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will launch a SARS-CoV-2 Rapid Antigen Test, in late September, for markets accepting the CE Mark. This can help healthcare professionals identify a SARS-CoV-2 infection in people suspected to carry the virus with results typically ready in 15 minutes.

Virus 52

Virus Laboratories Clinical Trials Treatment 52

PLOS: DNA Science

MARCH 30, 2023

The first genome sequence of SARS-CoV-2 was posted to the world astonishingly fast, on January 11, 2020. Comparing genome sequences is important because they provide a 4-letter language in the bases A, C, G, and T (for DNA) or A, C, G, and U (for RNA). 1 which begat BA1.1 as well as BA.2, I stopped updating once that happened.

DNA 52

DNA Hospitals Laboratories Virus 52

The Pharma Data

OCTOBER 19, 2020

20, 2020 /PRNewswire/ — Caris Life Sciences® , a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Winship Cancer Institute of Emory University (Winship) has joined Caris’ Precision Oncology Alliance (The Alliance/POA). IRVING, Texas and ATLANTA , Oct.

Clinical Trials 52

Clinical Trials RNA DNA Science 52

The Pharma Data

MARCH 11, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

Drug Target Review

SEPTEMBER 28, 2023

For security reasons, at the time COVID-19 had to be grown in BSL-3 labs, which can be dangerous because they were handling the live virus. These are synthetic, not the live virus, so do not pose a risk of infection. Researchers were able to use our synthetic RNA controls as a reference to verify and validate assays.

DNA 116

DNA Organic Chemistry Science Virus 116

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

SEPTEMBER 3, 2020

First commercial test for fully automated high throughput systems to detect and differentiate SARS-CoV-2, influenza A virus and/or influenza B virus with a single sample. The test has been authorised only for the detection of RNA from SARS-CoV-2 virus, Influenza A virus, and Influenza B virus and not any other viruses or pathogens.

FDA 40

FDA Virus Laboratories Clinical Trials 40

The Pharma Data

DECEMBER 19, 2020

20, 2020 02:44 UTC. Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. Healthcare workers have been on the front lines of the fight against the virus and are an inspiration to us all. government by the end of December 2020. CAMBRIDGE, Mass.–(

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

PLOS: DNA Science

OCTOBER 24, 2024

In those early days, politicians and government officials who’d never heard terms like “cytokine storm” and “RNA virus” were suddenly charged with explaining what was happening. adults given in December 2020 to 1,500 individuals and in March 2021 to another 1,015 people.

Science 52

Science Research Vaccine Government 52

The Pharma Data

DECEMBER 18, 2020

18, 2020 /PRNewswire/ — Today, the U.S. The Moderna COVID-19 Vaccine contains messenger RNA (mRNA), which is genetic material. The vaccine contains a small piece of the SARS-CoV-2 virus’s mRNA that instructs cells in the body to make the virus’s distinctive “spike” protein. The EUA Process.

Vaccine 52

Vaccine FDA Clinical Trials FDA Approval 52

The Pharma Data

DECEMBER 3, 2020

The company has not revealed where the problems occurred, but vaccines typically require materials that include antiviral agents, antiseptic liquids, sterile water, and the nucleic acids that make up the RNA of the virus that is used in the mRNA vaccines. That’s totally unprecedented.”.

Vaccine 52

Vaccine Government RNA FDA 52

The Pharma Data

OCTOBER 27, 2020

As part of those efforts, it has become increasingly clear that to tackle the pandemic at a global level the development of medicines that can prevent and treat the virus, in addition to the development of vaccines, will be crucial. These building blocks are designed to target different sites on the virus for multiple concurrent effects.

Therapies 52

Therapies Virus Treatment Clinical Trials 52